Skip to content

Pilot Feasibility of Rice Bran Supplementation in Children

Pilot Feasibility of Rice Bran Supplementation for Diarrheal Disease Prevention in Malian Children

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02557373
Enrollment
48
Registered
2015-09-23
Start date
2015-08-31
Completion date
2016-05-31
Last updated
2017-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dietary Rice Bran Supplementation

Keywords

rice bran, infants, stool metabolome and microbiome, dietary intervention

Brief summary

The purpose of this study is to assess feasibility of rice bran consumption in weaning children and to identify dietary rice bran mediated changes to the stool microbiome and stool metabolome.

Detailed description

Rice bran is a globally accessible, underutilized food ingredient with an array of beneficial nutrients (e.g. phytochemicals and prebiotics) that promote health and potentially prevent diseases. The investigators will determine if dietary rice bran intake can modulate the infant gut microbiome and metabolome to promote gut immunity for the benefit of preventing diarrheal diseases that increase risk for malnutrition and stunting. The investigators hope to learn about the feasibility of dietary supplementation of heat-stabilized rice bran in weaning children living in regions with increased susceptibility to diarrhea and malnutrition, and whether or not rice bran consumption can modulate the stool microbiome and metabolome.

Interventions

DIETARY_SUPPLEMENTVitamin A

100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation.

DIETARY_SUPPLEMENTRice Bran + Vitamin A

100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation. Dietary rice bran consumed daily and amounts increase throughout the 3 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 3 g/day)

Sponsors

University of the Sciences, Techniques and Technologies of Bamako
CollaboratorOTHER
Colorado State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
4 Months to 10 Months
Healthy volunteers
Yes

Inclusion criteria

* Children between the ages of 4-6 months at beginning of recruitment * Families willing to feed their infant a daily dose of study-provided heat-stabilized rice bran supplementation for 3 months * Hemoglobin level \>7 g/dl * Absence of intestinal parasites or malaria infection * Have not yet received Vitamin A supplementation

Exclusion criteria

* Have had a diarrheal episode between 5 and 6 months of age * Have had a prior hospitalization * Have had an antibiotic or prophylactic treatment within 1 month prior to participation * Have an ongoing illness, a known immunocompromising condition, or use of medications * Hemoglobin level \<7 g/dl * Presence of intestinal parasites or malaria infection

Design outcomes

Primary

MeasureTime frameDescription
Number of participants who are compliant to consuming rice bran daily and in amounts provided.3 monthsRecord daily rice bran consumption and track compliance to diet intervention by regular visits from local community health workers.

Secondary

MeasureTime frameDescription
Number of participants with microbial modulations in stool as detected by microbiome sequencing3 monthsMeasure the stool microbiome modulation with rice bran consumption for gut health and diarrhea prevention compared to a Vitamin A supplementation alone.
Number of participants with metabolite modulations in stool as detected by Gas Chromatography-Mass Spectrometry (GC-MS) and Liquid Chromatography-Mass Spectrometry (LC-MS)3 monthsMeasure the stool metabolome modulation with rice bran consumption for gut health and diarrheal prevention compared to a Vitamin A supplementation alone.

Countries

Mali, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026